Study of a new drug for advanced tumors with RET gene changes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug, SNH-118110, for people with advanced solid tumors that have a specific genetic change called RET. It aims to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has not responded to standard treatment, or you cannot tolerate standard treatment.
- Your tumor has a specific genetic change called a RET fusion or other RET alteration (a test can confirm this).
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG performance status 0 or 1) and are expected to live at least 3 months.
- You do not have other major health problems that would make the trial unsafe, and you have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called SHR-8203 for people with advanced solid tumors that have stopped responding to standard treatments or for whom no standard treatment exists. The goal is to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called HRS-6208 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and if it can help shrink or control the cancer.
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
This trial tests a new combination of two study drugs (GH55 and GH21) for people with advanced solid tumors that have certain genetic changes. The goal is to see if the combo is safe and can help shrink tumors or slow their growth.
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.